ClinicalTrials.gg
CompletedNCT01110668Updated Feb 28, 2017

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

A Phase 2 interventional study of Nilotinib in Gastrointestinal Stromal Tumor, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.

Enrollment
13th of 14
2 · median 35
Started
2008
with 5 others
Phase 2
6 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
12 of 14
Novartis Pharmaceuticals

Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 13th largest by enrollment, is one of 6 that started in 2008, is one of 6 in phase 2, and was the 10th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors as a file.
02

Study summary

This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.

03

Conditions studied

  • Gastrointestinal Stromal Tumor

Keywords

  • Unresectable
  • metastatic gastrointestinal stromal tumor
  • disease progression
  • progression-free survival
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of GIST that is unresectable and/or
  • Radiological confirmation of disease progression or intolerance to imatinib therapy at a any dose
  • At least one measurable site of disease on CT scan at Visit-2
  • of 0, 1 or 2 at Visit-2
  • Patients must have normal organ, electrolyte, and marrow function at Visit-1 and Visit-2

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with nilotinib or any other tyrosine kinase inhibitors except imatinib.
  • Treatment with any cytotoxic and/or cytotoxic drug ≤ 4 weeks
  • Prior or concomitant other than GIST
  • Impaired cardiac function at Visit-1 or 2
  • Patients with severe and/or uncontrolled concurrent medical disease
  • Use of therapeutic coumarin derivatives
  • Use of any medications that prolong the
  • Use of inhibitors
  • Patients who have undergone major surgery ≤ 2 weeks prior to Visit-1 or who have not recovered from side effects of such surgery
  • Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation \< 2 weeks prior to Visit-1 or who have not recovered from side effects of such therapy

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Drug: Nilotinib

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.

    Time frame: every 8 weeks

Secondary outcomes

  1. To determine progression-free survival and the response rate of nilotinib in patients with advanced GIST previously treated with imatinib ≥600 mg.

    Time frame: 6 months

07

Study locations

4 sites
  • Novartis Investigative Site
    Adana, Turkey
  • Novartis Investigative Site
    Ankara, Turkey
  • Novartis Investigative Site
    Istanbul, Turkey
  • Novartis Investigative Site
    Izmir, Turkey
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2010
First posted
Apr 27, 2010
Start
Sep 2008
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01110668
Responsible party
Sponsor
First posted
Apr 27, 2010
Start date
Sep 2008
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Feb 28, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion